{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:23Z","timestamp":1777934543149,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Generally national guidelines for febrile neutropenia recommend treatment with cefepime 2\u2005g every 8\u2005h. Due to beta-lactam\u2019s time dependent killing effects, it is hypothesized smaller doses given more frequently might be non-inferior. The objective of this study is to retrospectively evaluate the efficacy of cefepime 1\u2005g every 6\u2005h versus 2\u2005g every 8\u2005h in cancer patients with febrile neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center, cohort study included patients with a diagnosis of febrile neutropenia treated with cefepime during an inpatient encounter. Patients were grouped based on receipt of cefepime 2\u2005g every 8\u2005h (high dose cohort) versus cefepime 1\u2005g every 6\u2005h (low dose cohort). The primary outcome compared the time to defervescence after cefepime initiation between the two dosing strategies. A subgroup analysis of the primary endpoint was conducted in patients who received both cefepime and vancomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-seven patients were included in the high dose cohort, and seventy-six patients were included in the low dose cohort. Baseline characteristics were similar between cohorts with the exception of race. The time to defervescence between the high dose cohort and low dose cohort were comparable between groups (49.2 vs. 46.7\u2005h). The time to defervescence in subgroup analysis of patients who received empiric vancomycin and cefepime was 65.7 versus 59.7.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients who received cefepime 1\u2005g every 6\u2005h were found to have similar trends in achieving time to defervescence compared to 2\u2005g every 8\u2005h.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221080078","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T11:18:04Z","timestamp":1644837484000},"page":"898-903","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-3120","authenticated-orcid":false,"given":"Lindsay","family":"Okubo","sequence":"first","affiliation":[{"name":"Enterprise Pharmacy, Geisinger Community Medical Center, Scranton, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Andrick","sequence":"additional","affiliation":[{"name":"Enterprise Pharmacy, Geisinger Medical Center, Danville, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky","family":"Rampulla","sequence":"additional","affiliation":[{"name":"Enterprise Pharmacy, Geisinger Medical Center, Danville, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Leri","sequence":"additional","affiliation":[{"name":"Enterprise Pharmacy, Geisinger Community Medical Center, Scranton, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"bibr1-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"bibr2-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6211"},{"key":"bibr3-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"bibr4-10781552221080078","author":"Baden LR","year":"2020","journal-title":"J Natl Compr Canc Ne"},{"key":"bibr5-10781552221080078","volume-title":"Maxipime (prescribing information)","author":"Hospira Inc","year":"2012"},{"key":"bibr6-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1853-1861.2003"},{"key":"bibr7-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.008"},{"key":"bibr8-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-15"},{"key":"bibr9-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220918638"},{"key":"bibr10-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01956-15"},{"key":"bibr11-10781552221080078","volume-title":"Poster session presented at: 49th Infectious Diseases Society of America (IDSA) annual meeting","author":"Helgeson MR","year":"2011"},{"key":"bibr12-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017696950"},{"key":"bibr13-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1503"},{"key":"bibr14-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200301000-00017"},{"key":"bibr15-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c0349e"},{"key":"bibr16-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.430"},{"key":"bibr17-10781552221080078","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl349"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221080078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221080078","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221080078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:40Z","timestamp":1777688800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221080078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/10781552221080078"],"URL":"https:\/\/doi.org\/10.1177\/10781552221080078","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}